JP2023538520A5 - - Google Patents
Info
- Publication number
- JP2023538520A5 JP2023538520A5 JP2023507879A JP2023507879A JP2023538520A5 JP 2023538520 A5 JP2023538520 A5 JP 2023538520A5 JP 2023507879 A JP2023507879 A JP 2023507879A JP 2023507879 A JP2023507879 A JP 2023507879A JP 2023538520 A5 JP2023538520 A5 JP 2023538520A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- patient
- further characterized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026060896A JP2026117027A (ja) | 2020-08-07 | 2026-04-02 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063011P | 2020-08-07 | 2020-08-07 | |
| US63/063,011 | 2020-08-07 | ||
| US202163173160P | 2021-04-09 | 2021-04-09 | |
| US63/173,160 | 2021-04-09 | ||
| US202163212463P | 2021-06-18 | 2021-06-18 | |
| US63/212,463 | 2021-06-18 | ||
| PCT/US2021/045000 WO2022032132A1 (en) | 2020-08-07 | 2021-08-06 | Advantageous therapies for disorders mediated by ikaros or aiolos |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026060896A Division JP2026117027A (ja) | 2020-08-07 | 2026-04-02 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538520A JP2023538520A (ja) | 2023-09-08 |
| JP2023538520A5 true JP2023538520A5 (cg-RX-API-DMAC7.html) | 2024-08-15 |
| JP7846086B2 JP7846086B2 (ja) | 2026-04-14 |
Family
ID=80118544
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507879A Active JP7846086B2 (ja) | 2020-08-07 | 2021-08-06 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
| JP2026060896A Pending JP2026117027A (ja) | 2020-08-07 | 2026-04-02 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026060896A Pending JP2026117027A (ja) | 2020-08-07 | 2026-04-02 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230190760A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192450A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7846086B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230049678A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116194438B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021322285B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002225A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173658A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300373A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001545A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI887465B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022032132A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| SMT202600194T1 (it) * | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| US11807620B2 (en) | 2020-02-21 | 2023-11-07 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| CA3194351A1 (en) * | 2020-10-14 | 2022-04-21 | Christopher G. Nasveschuk | Tricyclic compounds to degrade neosubstrates for medical therapy |
| JP7863100B2 (ja) * | 2020-10-14 | 2026-05-20 | シーフォー セラピューティクス, インコーポレイテッド | Ikzf2又はikzf4を分解する三環式リガンド |
| JP7807110B2 (ja) * | 2021-08-27 | 2026-01-27 | ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド | イソインドリノン化合物およびその使用 |
| JP2025505687A (ja) * | 2022-02-09 | 2025-02-28 | シーフォー セラピューティクス, インコーポレイテッド | Cft7455のモルフィック形態及びその製造方法 |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2024193641A1 (zh) * | 2023-03-21 | 2024-09-26 | 上海超阳药业有限公司 | 异吲哚啉衍生物和苯并吲哚衍生物及其应用 |
| JP2026524477A (ja) | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Krasの分解のためのヘテロ二官能性化合物 |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| CN121620373A (zh) * | 2024-07-26 | 2026-03-06 | 上海超阳药业有限公司 | 苯并吲哚衍生物的药物组合物、制备方法及用途 |
| WO2026065268A1 (en) * | 2024-09-29 | 2026-04-02 | Biofront Ltd | Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| CN120138159A (zh) * | 2025-04-30 | 2025-06-13 | 徐州医科大学 | Nup35基因作为胶质母细胞瘤诊断、预后及治疗靶点的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012175481A1 (en) * | 2011-06-20 | 2012-12-27 | Institut Curie | Compositions and methods for treating leukemia |
| CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
| EP4717317A3 (en) * | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN111902141A (zh) * | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| US10905684B2 (en) | 2018-06-13 | 2021-02-02 | Biotheryx, Inc. | Aminoamide compounds |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
-
2021
- 2021-08-06 AU AU2021322285A patent/AU2021322285B2/en active Active
- 2021-08-06 WO PCT/US2021/045000 patent/WO2022032132A1/en not_active Ceased
- 2021-08-06 BR BR112023002225A patent/BR112023002225A2/pt unknown
- 2021-08-06 CA CA3173658A patent/CA3173658A1/en active Pending
- 2021-08-06 KR KR1020237007995A patent/KR20230049678A/ko active Pending
- 2021-08-06 MX MX2023001545A patent/MX2023001545A/es unknown
- 2021-08-06 CN CN202180066994.5A patent/CN116194438B/zh active Active
- 2021-08-06 IL IL300373A patent/IL300373A/en unknown
- 2021-08-06 JP JP2023507879A patent/JP7846086B2/ja active Active
- 2021-08-06 TW TW110129154A patent/TWI887465B/zh active
- 2021-08-06 EP EP21853504.5A patent/EP4192450A4/en active Pending
-
2023
- 2023-02-07 US US18/106,893 patent/US20230190760A1/en active Pending
-
2026
- 2026-04-02 JP JP2026060896A patent/JP2026117027A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eshghpour et al. | Effect of menstrual cycle on frequency of alveolar osteitis in women undergoing surgical removal of mandibular third molar: a single-blind randomized clinical trial | |
| Grushka et al. | Burning mouth syndrome | |
| Rieke et al. | Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials | |
| Persson et al. | Influence of Parkinson's disease on oral health | |
| JP6891385B2 (ja) | トラジピタントによる治療方法 | |
| Pereira et al. | Effect of preemptive analgesia with ibuprofen in the control of postoperative pain in dental implant surgeries: a randomized, triple-blind controlled clinical trial | |
| Xia et al. | Expert consensus on the prevention and treatment of radiochemotherapy-induced oral mucositis | |
| Paiva-Oliveira et al. | Comparison of the anti-inflammatory effect of dexamethasone and ketorolac in the extractions of third molars | |
| Bhadage et al. | Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis | |
| JP2024516795A (ja) | エベロリムスおよびアムセネストラントを含む組合せ物 | |
| Ideo et al. | Prevalence of apical periodontitis in patients with autoimmune diseases under immunomodulators: a retrospective cohort study | |
| CN110013478A (zh) | 用于抗肿瘤试剂施用的方法 | |
| Scott et al. | Donor site wound healing following free gingival graft surgery using platelet rich fibrin: A randomized controlled trial | |
| Çankaya et al. | Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study | |
| Bhatia et al. | Topical phenytoin suspension and normal saline in the treatment of leprosy trophic ulcers: a randomized, double‐blind, comparative study | |
| JP2025505687A5 (cg-RX-API-DMAC7.html) | ||
| Kalogirou et al. | mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus | |
| Lee et al. | Extraction of mandibular third molars: relationship of preoperative anxiety with body mass index, serum high-sensitivity C-reactive protein levels, and visual analog scale scores and predictors of postoperative complications | |
| Jivanescu et al. | Effects of a Hydrogel Patch on Denture‐Related Traumatic Ulcers; an Exploratory Study | |
| Eslamian et al. | The effect of naproxen patches on relieving orthodontic pain by evaluation of VAS and IL-1β inflammatory factor: a split-mouth study | |
| Meaney et al. | Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication | |
| Alexander | Clinical experience with naproxen in rheumatoid arthritis | |
| Gusmão et al. | Evaluation of a mucoadhesive pilocarpine tablet for the treatment of xerostomia: A randomized, double-blind, crossover clinical trial | |
| Deen et al. | Successful treatment of recurrent aphthous ulcers with nicotine lozenges in a lifelong non-smoker. | |
| JPH0276813A (ja) | 神経変性疾患の治療薬 |